A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Date
2022
Author
Kwong, Ava
Tibau, Ariadna
Kuemmel, Sherko
Campone, Mario
Loirat, Delphine
Lopez Lopez, Rafael
Beck, J. Thaddeus
De Laurentiis, Michelino
Im, Seock-Ah
Kim, Sung-Bae
Steger, Guenther G.
Adelantado, Esther Zamora
Duhoux, Francois P.
Greil, Richard
Kuter, Irene
Lu, Yen-Shen
ÖZGÜROĞLU, Mustafa
Scholz, Christian W.
Singer, Christian F.
Vega, Estela
Wimberger, Pauline
Zamagni, Claudio
Couillebault, Xuan-Mai
Fan, Liqiong
Guerreiro, Nelson
Mataraza, Jennifer
Sand-Dejmek, Janna
Chan, Arlene
Metadata
Show full item record
Abstract
Purpose: This phase II study determined the efficacy of lacnotuzumab added to gemcitabine plus carboplatin (gem-carbo) in patients with advanced triple-negative breast cancer (TNBC).
URI
http://hdl.handle.net/20.500.12627/184217
https://doi.org/10.1158/1078-0432.ccr-20-3955
Collections